Advice
Relevance to NICE guidance programmes
Relevance to NICE guidance programmes
Subcutaneous trastuzumab was not considered appropriate for a NICE technology appraisal and is not currently planned within any other NICE work programme.
Guidance issued by NICE which recommends trastuzumab as an option in breast cancer in certain circumstances was based on consideration of the evidence relating to intravenous administration of the drug:
-
The use of trastuzumab for the treatment of advanced breast cancer (NICE technology appraisal guidance 34).
-
Early and locally advanced breast cancer: diagnosis and treatment (NICE clinical guideline 80), which updated Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (NICE technology appraisal guidance 107).
-
Advanced breast cancer: diagnosis and treatment (NICE clinical guideline 81).
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (NICE technology appraisal guidance 257) does not recommend trastuzumab in combination with an aromatase inhibitor for first-line treatment in postmenopausal women with metastatic hormone-receptor-positive breast cancer that overexpresses HER2.